Skip to main content

Cambrex Corp Value Stock - Dividend - Research Selection

Cambrex Corp

ISIN: US1320111073, WKN: 874318

Market price date: 30.11.-0001
Market price: 0,00 USD




Cambrex Corp Fundamental data and company key figures of the share

Annual reports in USD
Key figures 15-02-2019
Cash flow
Net operating cash flow 86.982.000
Capital Expenditures -62.598.000
Free cash flow 24.384.000
Balance sheet
Total Equity 653.727.000
Liabilities & Shareholders equity 1.223.430.000
Income statement
Net income 92.418.000
Eps (diluted) 2,750
Diluted shares outstanding 33.665.000
Net sales/revenue 532.093.000

Fundamental ratios calculated on: 30-11--0001

Ratios
Key figures 30-11--0001
Cash flow
P/C 0,00
   
P/FC 0,00
Balance sheet
ROI0,00
ROE0,00
Income statement
P/E0,00
Div. Yield0,00%
P/B0,00
P/S0,00


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolCBM
Market Capitalization2.019.563.392,00 USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internetwww.cambrex.com


Description of the company

Cambrex Corporation (the "Company" or "Cambrex"), a Delaware corporation, began business in December 1981. Cambrex is a life sciences company that provides products and services that accelerate and improve the development and commercialization of new and generic therapeutics. The Company primarily supplies its products and services worldwide to innovator and generic pharmaceutical companies. The Company's overall strategy is to: grow its portfolio of custom development projects, especially those in the later stages of the clinical trial process; secure long-term supply agreements to produce active pharmaceutical ingredients (“APIs”) and intermediates for newly approved drug products; expand sales of products and projects based on its proprietary technologies; partner with generic drug companies to grow the Company’s extensive portfolio of generic APIs; and develop, or co-develop with partners, a portfolio of niche generic drug products in finished dosage form. The Company also seeks to demonstrate excellence in regulatory compliance, environmental, health and safety, and customer service. Cambrex has four operating segments, which are manufacturing facilities that have been aggregated as one reportable segment.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.cambrex.com